Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N, Okamoto M, Kawashima Y, Okamoto I. Ishii H, et al. Among authors: kurata t. Thorac Cancer. 2023 Jan;14(1):105-107. doi: 10.1111/1759-7714.14727. Epub 2022 Nov 15. Thorac Cancer. 2023. PMID: 36380738 Free PMC article.
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S, Chihara Y, Okada A, Horiuchi S, Hibino M, Uryu K, Honda R, Yamanaka Y, Yoshioka H, Kurata T, Takayama K. Takeda T, et al. Among authors: kurata t. Cancers (Basel). 2023 Feb 28;15(5):1543. doi: 10.3390/cancers15051543. Cancers (Basel). 2023. PMID: 36900334 Free PMC article.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, Chihara Y, Takei S, Kawachi H, Yamada T, Tamiya N, Okura N, Yamada T, Murai J, Shiotsu S, Kurata T, Takayama K. Tanimura K, et al. Among authors: kurata t. Cancers (Basel). 2023 Oct 14;15(20):4988. doi: 10.3390/cancers15204988. Cancers (Basel). 2023. PMID: 37894357 Free PMC article.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y, Takei S, Kawachi H, Nakanishi K, Yamanaka Y, Tamiya N, Honda R, Okura N, Yamada T, Uryu K, Murai J, Shiotsu S, Yoshioka H, Yamada T, Kurata T, Takayama K. Yoshimura A, et al. Among authors: kurata t. Front Oncol. 2024 Jan 26;14:1303543. doi: 10.3389/fonc.2024.1303543. eCollection 2024. Front Oncol. 2024. PMID: 38344209 Free PMC article.
Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer.
Yamanaka Y, Ota T, Masuoka Y, Takeyasu Y, Nakamura S, Terashima M, Yoshioka H, Fukuoka M, Kurata T. Yamanaka Y, et al. Among authors: kurata t. Cancers (Basel). 2024 Sep 11;16(18):3127. doi: 10.3390/cancers16183127. Cancers (Basel). 2024. PMID: 39335099 Free PMC article.
991 results